Clinical Commander

Back to dossier
cardio.dvt.travel-related.v1PRODUCTION
cardio.dvt.travel-related.v1

Travel-associated DVT (long-haul flight or train >4 h)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Travel-associated DVT = provoked VTE with a major reversible transient risk factor (immobility >4 h); 3-mo AC sufficient (ACCP 2021); future-flight prevention is the differentiator. Route to cardio.dvt.core.v1 for diagnostic arc + DOAC chronic regimen

Inputs
1
Actions
0
Advance rule
Set
Advance when

travel-associated DVT framed

Patient inputs (10)

Risk increases with age >60; travel-associated VTE in younger patients should prompt thrombophilia screen (especially if family history positive)

Female + OCP / hormone use compounds risk; pregnancy / postpartum is a separate pathway (cardio.dvt.pregnancy.v1)

Prior VTE, OCP / HRT, active malignancy, obesity BMI ≥30, recent surgery / trauma, varicose veins, known thrombophilia — drives baseline risk band and prevention plan for future travel

Document hours airborne or in continuous transport; >4 h is threshold; >8 h is high; multiple legs within same trip aggregate risk

Unilateral leg swelling is the cardinal symptom; bilateral suggests systemic etiology (HF, cirrhosis, nephrotic) and lowers DVT probability

Initial confirmation of DVT (proximal vs distal); femoral + popliteal compression test

Age-adjusted D-dimer (cutoff = age × 10 ng/mL FEU if >50) rules out DVT in low-intermediate Wells

Baseline Hgb + platelet for AC bleed risk; isolated thrombocytopenia after travel + recent illness can be coincident, screen if abnormal

HAS-BLED + recent surgery + falls history determines AC eligibility and choice

eGFR for DOAC dosing — apixaban dose-reduction criteria, rivaroxaban CrCl <30 caution

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningconcurrent_pe_developing_during_or_after_long_haul_flight
    Travel-related DVT with new pleuritic chest pain, dyspnea, hypoxia, syncope, or hemodynamic instability — concurrent PE
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningphlegmasia_from_massive_iliofemoral_post_flight
    Massive acute occlusive iliofemoral DVT post-flight producing phlegmasia cerulea dolens (cyanosis, severe pain, arterial compromise)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmajor_bleed_during_AC_for_travel_dvt
    Major bleed on DOAC during 3-mo treatment course for travel-associated DVT (Hgb drop ≥2 g/dL, transfusion, ICH, retroperitoneal)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_dvt_with_future_travel_no_prophylaxis
    Patient with prior travel-related DVT develops new DVT after another long-haul trip without having taken pre-flight LMWH or stockings
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremay_thurner_unmasked_during_travel_dvt_workup
    Left iliofemoral DVT after long-haul travel in young woman → venogram or MRV reveals iliac vein compression (Cockett lesion)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

ENTRYrequiredDrives risk stratification
Loading…

Recommended regimen

Travel-associated DVT — 3-mo provoked AC + structured future-travel prevention plan (ACCP 2021; Watson + Baglin 2011)
axis: travel_associated_dvt_provoked_phenotype
Selected axis "Travel-associated DVT — 3-mo provoked AC + structured future-travel prevention plan (ACCP 2021; Watson + Baglin 2011)" by default fallback (first axis)
  • apixaban
    first line
    doac_factor_xa_direct
    10 mg BID × 7 d → 5 mg BID • PO • BID × 3 months total then STOP
    triggers: travel_provoked_dvt_no_active_bleed, egfr_above_25
    AMPLIFY (Agnelli NEJM 2013 PMID 23808982) — apixaban first-line; ACCP 2021 strong recommendation; provoked-by-reversible-factor → 3 mo sufficient
    rxcui 1364430
  • rivaroxaban
    first line
    doac_factor_xa_direct
    15 mg BID × 21 d → 20 mg daily with food • PO • BID then daily × 3 months total then STOP
    triggers: travel_provoked_dvt_no_active_bleed, egfr_above_30
    EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814) — non-inferior; common alternative DOAC
    rxcui 1114195
  • enoxaparin
    first line
    lmwh
    1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 • SC • BID × 5-10 d as bridge to warfarin, OR single 40 mg dose pre-flight for high-risk prevention
    triggers: warfarin_bridge, pregnancy, severe_renal_impairment_doac_unsafe, high_risk_future_long_haul_travel
    ASH 2020 (PMID 33007077); Watson + Baglin 2011 — single LMWH dose 2-4 h pre-flight for high-risk patients (prior VTE, active cancer)
    rxcui 67108
  • edoxaban
    first line
    doac_factor_xa_direct
    60 mg PO daily (30 mg if CrCl 15-50, weight ≤60 kg, or with strong P-gp inhibitor) after 5-10 d LMWH bridge • PO • daily × 3 months total then STOP
    triggers: post_lmwh_bridge, doac_alternative_preference
    Hokusai-VTE (Büller NEJM 2013 PMID 23991958) — edoxaban after LMWH lead-in non-inferior to warfarin
    rxcui 1599538
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg daily; INR target 2-3 • PO • daily × 3 months total then STOP
    triggers: severe_renal_impairment_doac_unsafe, cost_constraint, antiphospholipid_syndrome_triple_positive
    TRAPS (Pengo Blood 2018 PMID 30002145) — warfarin > rivaroxaban in triple-positive APS; reasonable alternative if DOAC contraindicated
    rxcui 11289
  • aspirin
    contraindication substitute
    antiplatelet_cox1
    NOT RECOMMENDED for travel VTE prevention (documented as anti-recommendation only) • PO • n/a
    triggers: avoid_for_travel_prevention
    Cochrane 2006/2016 + LONFLIT-3 + WRIGHT 2007 — no benefit for travel VTE prevention; possible bleed harm; explicitly listed as not-recommended in Watson + Baglin 2011 and ACCP 2021. Listed here as anti-recommendation; do NOT prescribe ASA for travel VTE prevention
    rxcui 243670

outpatient playbook — drug actions (2)

  1. 1. no maintenance AC after 3 mo for travel-provoked DVT
    rxcui 1364430
    AC stopped at 3 mo for provoked reversible factor • PO • n/a
    trigger: Standard provoked VTE pathway
    ACCP 2021 strong recommendation
  2. 2. enoxaparin single dose pre-flight if high-risk
    rxcui 67108
    40 mg SC 2-4 h pre-flight • SC • one-time per long-haul flight
    trigger: High-risk patient (prior VTE, active cancer, known thrombophilia) planning long-haul flight >4 h
    Watson + Baglin 2011; LONFLIT-2 — single LMWH dose effective for high-risk prevention

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Unilateral leg swelling, calf pain, or whole-leg swelling within hours to ~4 weeks of long-haul travel >4 h (flight or train) — pretest probability for travel-associated DVT; Documented flight or continuous transport >4 h within the prior 4 weeks (peak risk window per LONFLIT) — anchor the provoking factor; New pleuritic chest pain, dyspnea, syncope, or hemoptysis within 4 weeks of long-haul travel — concurrent PE screen indicated (PERC fail in this context; CTPA if Wells > 4).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Travel-associated DVT (long-haul flight or train >4 h)** (cardio.dvt.travel-related.v1).
Scope: Travel-associated DVT = provoked VTE with a major reversible transient risk factor (immobility >4 h); 3-mo AC sufficient (ACCP 2021); future-flight prevention is the differentiator. Route to cardio.dvt.core.v1 for diagnostic arc + DOAC chronic regimen

No severity triggers fired against current inputs.

Plan

Regimen axis: **Travel-associated DVT — 3-mo provoked AC + structured future-travel prevention plan (ACCP 2021; Watson + Baglin 2011)**.
1. apixaban 10 mg BID × 7 d → 5 mg BID PO BID × 3 months total then STOP (doac_factor_xa_direct, first line) — AMPLIFY (Agnelli NEJM 2013 PMID 23808982) — apixaban first-line; ACCP 2021 strong recommendation; provoked-by-reversible-factor → 3 mo sufficient
2. rivaroxaban 15 mg BID × 21 d → 20 mg daily with food PO BID then daily × 3 months total then STOP (doac_factor_xa_direct, first line) — EINSTEIN-DVT (Bauersachs NEJM 2010 PMID 21128814) — non-inferior; common alternative DOAC
3. enoxaparin 1 mg/kg SC BID; reduce to 1 mg/kg daily if CrCl <30 SC BID × 5-10 d as bridge to warfarin, OR single 40 mg dose pre-flight for high-risk prevention (lmwh, first line) — ASH 2020 (PMID 33007077); Watson + Baglin 2011 — single LMWH dose 2-4 h pre-flight for high-risk patients (prior VTE, active cancer)
4. edoxaban 60 mg PO daily (30 mg if CrCl 15-50, weight ≤60 kg, or with strong P-gp inhibitor) after 5-10 d LMWH bridge PO daily × 3 months total then STOP (doac_factor_xa_direct, first line) — Hokusai-VTE (Büller NEJM 2013 PMID 23991958) — edoxaban after LMWH lead-in non-inferior to warfarin
5. warfarin 5 mg daily; INR target 2-3 PO daily × 3 months total then STOP (vitamin_k_antagonist, comorbidity specific) — TRAPS (Pengo Blood 2018 PMID 30002145) — warfarin > rivaroxaban in triple-positive APS; reasonable alternative if DOAC contraindicated
6. aspirin NOT RECOMMENDED for travel VTE prevention (documented as anti-recommendation only) PO n/a (antiplatelet_cox1, contraindication substitute) — Cochrane 2006/2016 + LONFLIT-3 + WRIGHT 2007 — no benefit for travel VTE prevention; possible bleed harm; explicitly listed as not-recommended in Watson + Baglin 2011 and ACCP 2021. Listed here as anti-recommendation; do NOT prescribe ASA for travel VTE prevention

Setting playbook (outpatient) — Post-AC long-term follow-up: PTS surveillance, future-travel prevention plan execution, address any persistent additive risk factors
7. no maintenance AC after 3 mo for travel-provoked DVT AC stopped at 3 mo for provoked reversible factor PO n/a — Standard provoked VTE pathway (ACCP 2021 strong recommendation)
8. enoxaparin single dose pre-flight if high-risk 40 mg SC 2-4 h pre-flight SC one-time per long-haul flight — High-risk patient (prior VTE, active cancer, known thrombophilia) planning long-haul flight >4 h (Watson + Baglin 2011; LONFLIT-2 — single LMWH dose effective for high-risk prevention)

Non-pharmacologic actions:
- Graduated compression stockings 15-30 mmHg below knee for moderate-risk on every long-haul flight
- Hydration + walking / calf exercises every 1-2 h on flight
- Aisle seat preferred for high-risk
- AVOID aspirin for travel VTE prevention (Cochrane / WRIGHT 2007)
- OCP discussion: switch to non-oestrogen contraception if recurrent travel-VTE history

AVOID / contraindication checks:
- Doac_avoid_active_bleeding (FDA labels)
- Apixaban_avoid_egfr_below_15 (FDA label)
- Rivaroxaban_avoid_egfr_below_30 (FDA label)
- Warfarin_avoid_pregnancy_use_lmwh (ASH 2018)
- Decision:stop_AC_at_3_months_for_provoked_reversible_factor (ACCP 2021 strong)
- Decision:asa_not_recommended_for_travel_vte_prevention (Cochrane / WRIGHT 2007 / Watson 2011)
- Decision:thrombophilia_testing_only_if_young_recurrent_strong_family_history (ASH 2018 PMID 30482764)

Monitoring

Regimen monitoring:
- cbc creatinine at 4 weeks then 3 months (DOAC label monitoring)
- pts villalta at 3 6 12mo (Kahn Lancet 2014)
- symptom recheck at 2 weeks then 3 months for AC stop decision (ACCP 2021)
- compression stocking 30 40mmhg if symptomatic pts (ATTRACT subgroup)
- future travel prevention education at AC stop visit (Watson 2011)

Setting (outpatient) monitoring:
- Annual PCP visit
- Pre-trip risk reassessment for any planned long-haul travel

Follow-up plan: Stop AC at 3 mo with symptom + reassessment visit; structured future-travel prevention plan: stockings 15–30 mmHg + hydration + walking for everyone; LMWH single dose pre-flight if high-risk (prior VTE, active cancer, known thrombophilia + planned >4 h flight); reinforce that ASA is NOT recommended for travel VTE prevention (Cochrane / WRIGHT 2007)
- Close-out criterion: AC stop date + future-travel prevention plan documented

Monitoring phase: Symptom resolution at 2 weeks; PTS Villalta at 3 / 6 / 12 mo; bleed surveillance during AC; compression stocking 30–40 mmHg if symptomatic for PTS prevention

Disposition

Current setting: outpatient — Post-AC long-term follow-up: PTS surveillance, future-travel prevention plan execution, address any persistent additive risk factors

Disposition criteria:
- Indefinite annual follow-up with structured pre-trip risk reassessment

Escalation triggers (move to higher acuity):
- New VTE despite prevention plan → restart AC + evaluate for thrombophilia + consider extended-phase AC
- Pregnancy → switch to LMWH per ASH 2018

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Travel-related DVT with new pleuritic chest pain, dyspnea, hypoxia, syncope, or hemodynamic instability — concurrent PE
- [LIFE_THREATENING] Massive acute occlusive iliofemoral DVT post-flight producing phlegmasia cerulea dolens (cyanosis, severe pain, arterial compromise)
- [LIFE_THREATENING] Major bleed on DOAC during 3-mo treatment course for travel-associated DVT (Hgb drop ≥2 g/dL, transfusion, ICH, retroperitoneal)

Citations

- ACCP/CHEST 2021 (Stevens) + Watson + Baglin 2011 BCSH travel thrombosis + ASH 2020 VTE Treatment [PMID:34352295](https://pubmed.ncbi.nlm.nih.gov/34352295/)
- Cited evidence (PMID 33007077) [PMID:33007077](https://pubmed.ncbi.nlm.nih.gov/33007077/)
- Cited evidence (PMID 21118201) [PMID:21118201](https://pubmed.ncbi.nlm.nih.gov/21118201/)
- Cited evidence (PMID 23808982) [PMID:23808982](https://pubmed.ncbi.nlm.nih.gov/23808982/)
- Cited evidence (PMID 23216615) [PMID:23216615](https://pubmed.ncbi.nlm.nih.gov/23216615/)

Last reconciled with current guidelines: 2026-05-15.
References